Sugi Predict

Sugi Predict / Compounds / SCHEMBL798220

SCHEMBL798220

SCHEMBL798220

O=C(O)c1cnc[nH]c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.45
▸ CYP3A4 P08684 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ GABRA1 P14867 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ GABRR1 P24046 1/20 0.44
▸ GABRR2 P28476 1/20 0.44
▸ GABRA5 P31644 1/20 0.44
▸ GABRB2 P47870 1/20 0.44
▸ GABRA4 P48169 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.42
▸ DYRK1A Q13627 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ KDM6B O15054 2/20 0.42
▸ KDM4A O75164 2/20 0.42
▸ HIF1AN Q9NWT6 2/20 0.42
▸ KDM2A Q9Y2K7 2/20 0.42
▸ KDM4D Q6B0I6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1210877 0.81 SIRT3 (0.41) CYP3A4ALDH1A1TSHRGABRA1NFKB1
SCHEMBL27189368 0.81 ALDH1A1 (0.38) NAPRTCYP3A4ALDH1A1TSHRGABRA1
SCHEMBL10194200 0.76 MEN1 (0.44) ALDH1A1TSHRKDM4EMAPTTP53
SCHEMBL5821247 0.75 HRH4 (0.39) CYP3A4ALDH1A1TSHRGABRA1NFKB1
SCHEMBL28718733 0.74 QPCT (0.39) CYP3A4ALDH1A1TSHRKDM4ETP53
SCHEMBL24399569 0.72 IP6K1 (0.51) ALDH1A1TSHRKDM4EDYRK1AKDM6B
SCHEMBL30402359 0.72 IP6K1 (0.51) ALDH1A1TSHRKDM4EDYRK1AKDM6B
SCHEMBL30625419 0.72 KDM4E (0.45) ALDH1A1KDM4EMAPTNPC1TP53
SCHEMBL27871336 0.70 CYP3A4 (0.34) CYP3A4ALDH1A1TSHRGABRA1NFKB1
SCHEMBL1771094 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110156698-A The preparation method and purposes of 2- phenyl -1,6- dihydro-pyrimidin -5- formic acid derivates 沈阳海诺威医药科技有限公司 2019-08-23 — — CN claimed
US-20260007672-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2026-01-08 — — US disclosed
US-12491185-B2 Inhibitors of mPTP NRG THERAPEUTICS LTD (GB) 2025-12-09 — — US disclosed
EP-4652162-A1 INHIBITORS OF MPTP NRG Therapeutics LTD (GB) 2025-11-26 — — EP disclosed
US-20250177397-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2025-06-05 — — US disclosed
WO-2025096463-A1 PLK4 MODULATORS VIBLIOME THERAPEUTICS, LLC (US) 2025-05-08 — — WO disclosed
WO-2024153946-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2024-07-25 — — WO disclosed
CN-117777103-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2024-03-29 — — CN disclosed
CN-117720519-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2024-03-19 — — CN disclosed
CN-117720520-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2024-03-19 — — CN disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 — — US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 — — US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 — — US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 — — US disclosed
EP-1309565-B1 HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2008-04-09 — — EP disclosed
US-6878704-B2 Heterocyclic mutilin esters and their use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2005-04-12 — — US disclosed
US-20040058937-A1 Heterocyclic mutilin esters and their use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-03-25 — — US disclosed
EP-1309565-A1 HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2003-05-14 — — EP disclosed
WO-2002012199-A1 HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058937-A1 Heterocyclic mutilin esters and their use as antibacterials MLN, MSH2, MRPL21 NAPRT 2149/4885CYP3A4 1533/4885ALDH1A1 852/4885
US-12491185-B2 Inhibitors of mPTP PARK7, PINK1, SNCA NAPRT 1354/4885CYP3A4 927/4885ALDH1A1 415/4885
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET NAPRT 467/4885CYP3A4 384/4885ALDH1A1 76/4885
US-20250177397-A1 INHIBITORS OF MPTP PARK7, PINK1, SNCA NAPRT 1354/4885CYP3A4 927/4885ALDH1A1 415/4885
US-20260007672-A1 INHIBITORS OF MPTP PARK7, SNCA, CYC1 NAPRT 3655/4885CYP3A4 666/4885ALDH1A1 176/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET NAPRT 467/4885CYP3A4 384/4885ALDH1A1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.